Variability factors in the clinical response to recombinant antibodies and IgG Fc-containing fusion proteins

Bibliography

• TEILLAUD JL: Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges. Expert Opia Biol. Ther. (20005) 5\(Suppl. 1):S-S.
   Google Scholar
• BREEDVELD FC: Therapeutic monoclonal antibodies. Lancet (2000) 355:735–740.
   PubMed Web of Science ®Google Scholar
• BREKKE OH, SANDLIE I: Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat. Rev Drug Discov. (2003) 2:52–62.
   PubMed Web of Science ®Google Scholar
• REICHERT J, PAVOLU A: Monoclonal antibodies market. Nat. Rev Drug Discov. (2004) 3:383–384.
   PubMed Web of Science ®Google Scholar
• CHANG TW: The pharmacological basis of anti-IgE therapy. Nat. Biotechnol (2000) 18:157–162.
   PubMed Web of Science ®Google Scholar
• HOCHHAUS G, BROOKMAN L, FOX H et al: Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr. Med. Res. Opin. (2003) 19:491–498.
   PubMed Web of Science ®Google Scholar
• MAROTTE H, MASLINSKI W, MIOSSEC P: Circulating tumour necrosis factor-a bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. Arthritis Res. Ther. (2005) 7:R149–R155.
   Google Scholar
• MARTINEZ-BORRA J, LOPEZ-LARREA C, GONZALEZ S et al: High serum tumor necrosis factor-a levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Am. J. Castroenterol (2002) 97:2350–2356.
   PubMed Web of Science ®Google Scholar
• MUGNIER B, BALANDRAUD N, DARQUE A, ROUDIER C, ROUDIER J, REVIRON D: Polymorphism at position 308 of the tumor necrosis factor-a gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum. (2003) 48:1849–1852.
   PubMed Web of Science ®Google Scholar
• PADYUKOV L, LAMPA J, HEIMBURGER M et al: Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann. Rheum. Dis. (2003) 62:526–529.
   PubMed Web of Science ®Google Scholar
• CRIS WELL LA, LUM RE TURNER KN,et al.: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. (2004) 50:2750–2756.
   Google Scholar
• NEWTON J, BROWN MA, MILICIC A et al: The effect of HLA-DR on susceptibility to rheumatoid arthritis is influenced by the associated lymphotoxin-tumor necrosis factor haplotype. Arthritis Rheum. (2003) 48:90–96.
   PubMed Web of Science ®Google Scholar
• MARTINEZ A, SALIDO M, BONILLA G et al: Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients. Arthritis Rheum. (2004) 50:1077–1082.
   PubMed Web of Science ®Google Scholar
• LOUIS E, VERMEIRE S, RUTGEERTS P et al: A positive response to infliximab in Crohn's disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand. Castroenterol (2002) 37:818–824.
   PubMed Web of Science ®Google Scholar
• MICHELSON AD, FURMAN MI, GOLDSCHMIDT-CLERMONT P et al.: Platelet GP IIIa P1(A) polymorphisms display different sensitivities to agonists. Circulation (2000) 101:1013–1018.
   PubMed Web of Science ®Google Scholar
• WHEELER GL, BRADEN GA, BRAY PF, MARCINIAK SJ, MASCELLI MA, SANE DC: Reduced inhibition by abciximab in platelets with the P1A2 polymorphism. Am. Heart J. (2002) 143:76–82.
   PubMed Web of Science ®Google Scholar
• WEBER AA, JACOBS C, MEILA D et a/.:No evidence for an influence of the human platelet antigen-1 polymorphism on the antiplatelet effects of glycoprotein inhibitors. Pharmacogenetics (2002) 12:581–583.
   Google Scholar
• GORCHAKOVA 0, KOCH W, MEHILLI J etal.: PIA polymorphism of the glycoprotein Ma and efficacy of reperfusion therapy in patients with acute myocardial infarction. Thromb. Haemost. (2004) 91:141–145.
   Google Scholar
• COIFFIER B, HAIOUN C, KETTERER N et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter Phase II study. Blood (1998) 92: 1927-1932.
   Google Scholar
• BERINSTEIN NL, GRILLO-LOPEZ AJ,WHITE CA et al: Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol (1998) 9:995–1001.
   PubMed Web of Science ®Google Scholar
• PEDERSEN IM, BUHL AM, KLAUSEN P, GEISLER CH, JURLANDER J: The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood(2002) 99:1314–1319.
   PubMed Web of Science ®Google Scholar
• MANCHES 0, LUI G, CHAPEROT L et al.: In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood (2003) 101:949–954.
   Google Scholar
• GOLAY J, LAZZARI M, FACCHINETTI V et al: CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood. (2001) 98:3383–3389.
   PubMed Web of Science ®Google Scholar
• MANSHOURI T, DO KA, WANG X et al: Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood (2003) 101:2507–2513.
   PubMed Web of Science ®Google Scholar
• SEIDMAN AD, FORNIER MN, ESTEVA FJ et al: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. Clin. Oncol (2001) 19:2587–2595.
   Web of Science ®Google Scholar
• WINSTON JS, RAMANARYANAN J, LEVINE E: HER-2/neu evaluation in breast cancer are we there yet? Am. J. Pathol (2004) 121:S33–S49.
   Google Scholar
• NAGATA Y, LAN KH, ZHOU X et al: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 6:117–127.
   PubMed Web of Science ®Google Scholar
• KLOFT C, GRAEFE EU, TANSWELL P et al: Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients. Invest. New Drugs (2004) 22:39–52.
   PubMed Web of Science ®Google Scholar
• CARTRON G, DACHEUX L, SALLES G et al.: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcyRIIIa gene. Blood (2002) 99:754–758.
   PubMed Web of Science ®Google Scholar
• WENG WK, LEVY R: Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol (2003) 21:3940–3947.
   PubMed Web of Science ®Google Scholar
• ANOLIK JH, CAMPBELL D, FELGAR RE et al: The relationship of FcyRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. (2003) 48:455–459.
   PubMed Web of Science ®Google Scholar
• TREON SP, HANSEN M, BRANAGAN AR et al: Polymorphisms in FcyRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. ./. Clin. Oncol. (2005) 23:474–481.
   PubMed Web of Science ®Google Scholar
• FARAG SS, FLINN IW, MODALI R, LEHMAN TA, YOUNG D, BYRD JC: FcyRIIIa and FcyRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood (2004) 103:1472–1474.
   PubMed Web of Science ®Google Scholar
• UN TS, FLINN IW, MODALI R et al: FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood (2005) 105:289–291.
   PubMed Web of Science ®Google Scholar
• MIESCHER S, SPYCHER MO, AMSTUTZ H et al: A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the FcyRIIA and FryIIIA genes. Blood (2004) 103:4028–4035.
   PubMed Web of Science ®Google Scholar
• LOUIS E, EL GHOUL Z, VERMEIRE S et al: Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment. Pharmacol Ther. (2004) 19:511–519.
   PubMed Web of Science ®Google Scholar
• RICHEZ C, DOLOMIE L, DUMOULIN C et al: Etude du polymorphisme FCGR3A-158 comme facteur prédictif de la reponse a l'infliximab dans la polyarthrite rhumato'ide et la spondylarthrite ankylosante. Rev Rhum. (2004) 71:1067.
   Google Scholar
• CRIS WELL LA, LUM RF, TURNER KNet al.: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. (2004) 50:2750–2756.
   Google Scholar
• STURM A, FIOCCHI C: Life and death in the gut: more killing, less Crohn's. Gut. (2002) 50:148–149.
   PubMed Web of Science ®Google Scholar
• KOENE HR, KLEIJER M, ALGRA J, ROOS D, VON DEM BORNE AE, DE HAAS M: Fc yRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FcyRIIIa, independently of the FcyRIIIa-48L/R/H phenotype. Blood (1997) 90:1109–1114.
   PubMed Web of Science ®Google Scholar
• WU J, EDBERG JC, REDECHA PB et al: A novel polymorphism of FcyRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J. Clin. Invest. (1997) 100:1059–1070.
   PubMed Web of Science ®Google Scholar
• OKAZAKI A, SHOJI-HOSAKA E, NAKAMURA K et al: Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcyRIIIa. Mai Biol. (2004) 336:1239–1249.
   PubMed Web of Science ®Google Scholar
• DALLOZZO S, TARTAS S, PAINTAUD G et al: Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. (2004) 64:4664–4669.
   PubMed Web of Science ®Google Scholar
• SALMON JE, EDBERG JC, BROGLE NL, KIMBERLY RP: Allelic polymorphisms of human Fey receptor IIA and Fey receptor IIIB. Independent mechanisms for differences in human phagocyte function. J. Clin. Invest. (1992) 89:1274–1281.
   Google Scholar
• PENDLEY C, SCHANTZ A, WAGNER C: Immunogenicity of therapeutic monoclonal antibodies. Curr. Opin. Mol. Ther. (2003) 5:172–179.
   PubMedGoogle Scholar
• BAERT F, NOMAN M, VERMEIRE S et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl. Med. (2003) 348:601–608.
   PubMed Web of Science ®Google Scholar
• MIELE E, MARKOWITZ JE, MAMULA P, BALDASSANO RN: Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. Pediatr. Gastroenterol Nutr. (2004) 38:502–508.
   PubMed Web of Science ®Google Scholar
• BRUGGEMANN M, WINTER G, WALDMANN H, NEUBERGER MS: The immunogenicity of chimeric antibodies. ./. Exp. Med. (1989) 170:2153–2157.
   PubMed Web of Science ®Google Scholar
• GORDAN LN, GROW WB, PUSATERI A, DOUGLAS V, MENDENHALL NP, LYNCH JW: Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. ./. Oncol (2005) 23:1096–1102.
   PubMed Web of Science ®Google Scholar
• SHIELDS RU, NAMENUK AK, HONG K et al: High resolution mapping of the binding site on human IgG1 for FcyRI, FcyRII, FcyRIII, and FcRn and design of IgG1 variants with improved binding to the FcyR. J. Biol. Chem. (2001) 276:6591–6604.
   PubMed Web of Science ®Google Scholar
• UMANA P, JEAN-MAIRET J, MOUDRY R, AMSTUTZ H, BAILEY JE: Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol (1999) 17:176–180.
   PubMed Web of Science ®Google Scholar
• SHIELDS RL, LAI J, KECK R et al.: Lackof fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcy RIII and antibody-dependent cellular toxicity. J. Biol. Chem. (2002) 277:26733–26740.
   PubMed Web of Science ®Google Scholar
• NIWA R, HATANAKA S, SHOJI6HOSAKA E et al.: Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 is independent of FcyRIIIa functional polymorphism. Clin. Cancer Res. (2004) 10:6248–6255.
   Google Scholar